Business
InMed Announces Non-Brokered Private Placement
InMed Announces Non-Brokered Private Placement Canada NewsWire VANCOUVER, Dec. 1...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Announces Non-Brokered Private Placement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Dec. 18, 2017\n\n\n\nCSE: INOTCQB: IMLFF\n\n/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES/\n\n\n\nVANCOUVER, Dec. 18, 2017 /CNW/ - InMed Pharmaceuticals, Inc. (\"InMed\" or the \"Company\") (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announces a non-brokered private placement (the \"Offering\") of up to 3,572,000 units at a price of CAD$0.70 per unit (each a \"Unit\") for aggregate gross proceeds of up to CAD$2,500,000. Each Unit will consist of one common share and one non-transferable share purchase warrant (the \"Warrant\").  Each Warrant will be exercisable by the holder to acquire one additional common share at a price of CAD$1.25 for a period of 18 months from the closing of the Offering. Separate Closings for individual subscriptions upon acceptance by the Company may take place at such time as the Company may determine.  Closings are anticipated to commence on or before December 22, 2017 or at such other time or times the Company may determine.\n\nThe Offering is being made to \"accredited investors\" under applicable exemptions from prospectus requirements, and may include one or more subscriptions by insiders and other existing shareholders of the Company.  All or a portion of this Offering could be subject to finder's fees or commissions. The private placement is subject to the approval of the Canadian Securities Exchange and the securities will be subject to a four month hold period under securities laws. \n\nThe Company intends to use the net proceeds from the private placement to advance the Company's drug development programs and for general working capital and corporate purposes.\n\nAbout InMed \n\nInMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription dr...